[1] Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol [J]. Clin Pharmacok inet, 1994, 26 (5): 335-346. [2] Chen Bonnie, ChowMoses SS. Focus on carvedilol: A Novel beta-adrenergic blocking agent for the treatment of congestive heart failure [J]. Formulary, 1997, 32: 795-805. [3] Neugebauer G, AkpanW. Pharmacokinetics and disposition of carvedilol in humans [J]. J Cardiovasc Pharmacol, 1987, 10 (suppl 11): 85-88. [4] Odeberg JM, Kaufmann P. Lipid drug delivery and rational formulation design for lipophilic drugswith low oral bioavailability, applied to cyclosporine [J]. Eur J Pharm Sci, 2003, 20 (4): 375-382. [5] Attama AA, Nzekwe IT. The use of solid self-emulsifying systems in the delivery of diclofenac [J]. Int J Pharmaceutics (Nigeria) , 2003, 262: 23-28. [6] Panayiotis P, Constantinides. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects [J]. Pharm Res, 1995, 12 (11): 1561-1572. [7] Pouton CW. Effects of inclusion of a model drug on the performance of self-emulsifying formulations [J]. J Pharm Pharmacol, 1985, 37 (1): 1-11. [8] Kommuru TR, Gurley B. Self2emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment [J]. Int J Pharmaceutics, 2001, 212: 233-246. [9] LevyMY, Benita S. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluationmodel [J]. Int J Pharm , 1990, 66: 29-37. [10] Bok Ki Kang, Jin Soo Lee. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs [J]. Int J Pharmaceutics, 2004, 271: 65-73. [11] Chambin O, Jannin V. Influence of cryogenic grinding on properties of a self-emulsifying formulation [J]. Int J Pharmaceutics, 2004, 278: 79-89. [12] Ho-Jin Kim, Kyung Ae Yoon. Preparation and in vitro evaluation of self2microemulsifying drug delivery systems containing idebenone [J]. Drug Dev Ind Pharm, 2000, 26 (5): 523-529. |